The RTK inhibitor vandetanib specifically inhibits the activity of RET, EGFR and VEGFR-2 and -3 and is already approved in the European Union for the treatment of advanced, non-resectable medullary thyroid carcinoma (MTC), another rare subtype of TC1,2,9. The gene discussed is KDR; the disease is medullary thyroid gland carcinoma.